Webinar | Enabling Next-Generation AI in Autoimmune R&D
Enabling Next-Generation AI in Autoimmune R&D
Autoimmune diseases are dynamic, varied, and difficult to characterize using traditional clinical visits and static datasets. As drug developers rely on AI and biomarker-driven approaches to understand disease activity and therapeutic response, they face a fundamental limitation: most available data offers only isolated snapshots in time, missing the dynamic transitions that truly define immune-mediated conditions.
In this discussion, our speakers will explore how longitudinal, temporally relevant, multimodal data collected through direct connections with individuals can help unlock new opportunities across early R&D for immune-mediated diseases. Attendees will gain insights on how these data can be used to sharpen R&D confidence in early-phase programs and support AI-driven innovation in autoimmune drug development.
- Learn how to redesign your autoimmune data strategy by identifying gaps in current data sets and determining where continuous data collection can strengthen biomarkers and translational efforts.
- Apply real-world and molecular signals to detect early flare signatures and characterize transitions between disease states.
- Integrate longitudinal evidence into biomarker development decisions.
- Strengthen translational and early development strategy with time-based patterns in immune activity data.
Related work
Evidation Launches Temporal Proteomics Platform to Power Autoimmune Research
January 8, 2026
Evidation Shares Insights on Real-World GLP-1 Dosing Behaviors from Over 60,000 Individuals
December 16, 2025
Evidation Appoints Dr. Ghazanfar Khan as Chief Medical Officer
December 2, 2025